\-\ Texto\\:\\ \ \(0\)\
\-\ this\\ woman\\ is\\ status\\ post\\ craniotomy\\ for\\ breast\\ cancer\\ metastatic\\ to\\ brain\\ \\-\\ a\\ piece\\ of\\ history\\ that\\ was\\ witheld\\.\\ \\ prognosis\\ is\\ generally\\ improved\\ if\\ cerebral\\ metastatic\\ deposits\\ are\\ treated\\ or\\ removed\\.\\ \\ she\\ has\\ also\\ received\\ chemotherapy\\.\\ the\\ new\\ presence\\ of\\ drop\\ metastases\\ in\\ the\\ spine\\ has\\ a\\ poor\\ prognosis\\.\\ \\ these\\ spinal\\ lesions\\ may\\ have\\ resulted\\ from\\ direct\\ hematogenous\\ spread\\ to\\ nerve\\ roots\\ \\-\\ or\\,\\ they\\ may\\ be\\ \\"drop\\ mets\\"\\ from\\ the\\ previous\\ brain\\ lesions\\.\ \(0\)\
\-\ diffuse\\ nodular\\ areas\\ of\\ enhancement\\ along\\ the\\ surface\\ of\\ the\\ spinal\\ cord\\ and\\ about\\ the\\ nerve\\ roots\\ of\\ the\\ cauda\\ equina\\.\ \(0\)\
\-\ droplet\\ metastases\ \(0\)\
\-\ drop\\ metastases\\:\ \(0\)\
\-\ \\Â\\»\\ primitive\\ neuroectodermal\\ tumor\\ \\(pnet\\)\ \(0\)\
\-\ \\Â\\»\\ medulloblastoma\ \(0\)\
\-\ \\Â\\»\\ anaplastic\\ or\\ malignant\\ astrocytoma\ \(0\)\
\-\ \\Â\\»\\ ependymoma\ \(0\)\
\-\ \\Â\\»\\ germinoma\ \(0\)\
\-\ \\Â\\»\\ pineoblastoma\ \(0\)\
\-\ \\Â\\»\\ choroid\\ plexus\\ carcinoma\ \(0\)\
\-\ hematogenous\\ spread\\ from\\ primary\\ lung\\ or\\ breast\\ cancer\\,\\ melanoma\\,\\ non\\-hodgkin\\ lymphoma\ \(0\)\
\-\ less\\ likley\\.\\.\\.\ \(0\)\
\-\ \\Â\\»\\ arachnoiditis\ \(0\)\
\-\ \\Â\\»\\ granulomatous\\ disease\ \(0\)\
\-\ \\Â\\»\\ neurofibromatosis\ \(0\)\
\-\ \\â\\€\\¢\\ nf1\\ \\-\\ neurofibromas\ \(0\)\
\-\ \\â\\€\\¢\\ nf2\\ \\-\\ schwannoma\ \(0\)\
\-\ \\Â\\»\\ epidermoid\\ dissemination\ \(0\)\
\-\ this\\ 43\\-year\\-old\\ woman\\ has\\ a\\ history\\ of\\ breast\\ cancer\\.\ \(0\)\
\-\ intradural\\ extramedullary\\ spinal\\ metastases\\ occur\\ hematogenously\\ or\\ via\\ csf\\ seeding\\.\\ hematogenous\\ spread\\ is\\ most\\ common\\ and\\ usually\\ occurs\\ with\\ lung\\ and\\ breast\\ carcinomas\\,\\ and\\ melanoma\\.\\ cns\\ tumors\\ with\\ access\\ to\\ the\\ ventricular\\ system\\ such\\ as\\ medulloblastoma\\,\\ ependymoma\\,\\ and\\ choroid\\ plexus\\ carcinoma\\ or\\ aggressive\\ tumors\\ such\\ as\\ glioblastoma\\ multiforme\\ are\\ usually\\ responsible\\ for\\ csf\\ seeding\\.\\ cortical\\ tumors\\ that\\ breach\\ the\\ pial\\ surface\\ \\(like\\ metastases\\ and\\ oligodendroglioma\\)\\ may\\ also\\ cause\\ csf\\ spread\\.\ \(0\)\
\-\ drop\\ metastases\\ are\\ likely\\ to\\ be\\ found\\ in\\ the\\ pediatric\\ population\\,\\ where\\ they\\ are\\ related\\ to\\ medulloblastoma\\,\\ ependymoma\\,\\ choroid\\ plexus\\ tumors\\,\\ or\\ pineal\\ germ\\ cell\\ neoplasms\\.\\ these\\ lesions\\ typically\\ occur\\ in\\ the\\ dorsal\\ lower\\-thoracic\\ to\\ lumbar\\ spine\\,\\ with\\ the\\ nerve\\ roots\\ and\\ the\\ cauda\\ equina\\ as\\ common\\ sites\\ of\\ spread\\ \\-\\ probably\\ due\\ to\\ upright\\ posture\\ and\\ gravity\\.\ \(0\)\
\-\ mr\\ imaging\\ is\\ the\\ best\\ modality\\ to\\ use\\ to\\ evaluate\\ the\\ contents\\ of\\ the\\ spinal\\ canal\\ and\\ detect\\ drop\\ metastases\\.\\ subarachnoid\\ tumor\\ implants\\ are\\ typically\\ hyperintense\\ to\\ csf\\ on\\ t1\\ and\\ hypointense\\ on\\ t2\\.\\ \ \(0\)\
\-\ post\\-gadolinium\\ images\\ demonstrate\\ diffuse\\ linear\\ and\\ nodular\\ areas\\ of\\ enhancement\\ along\\ the\\ nerve\\ roots\\ and\\ the\\ peripheral\\ surface\\ of\\ the\\ cord\\.\\ \ \(0\)\
\-\ processes\\ such\\ as\\ arachnoiditis\\,\\ neurofibromatosis\\ and\\ granulomatous\\ disease\\ may\\ demonstrate\\ a\\ similar\\ nodular\\ enhancement\\ and\\ clinical\\ history\\ is\\ helpful\\ in\\ narrowing\\ the\\ differential\\.\\ arachnoiditis\\ may\\ show\\ clumping\\ of\\ nerve\\ roots\\.\ \(0\)\
\-\ depending\\ on\\ the\\ number\\ of\\ lesions\\,\\ position\\,\\ and\\ extent\\ of\\ lesions\\,\\ the\\ management\\ of\\ drop\\ metastases\\ may\\ consist\\ of\\ steroids\\,\\ local\\ radiation\\ therapy\\,\\ or\\ surgery\\.\ \(0\)\
\-\ Keywords\\ by\\ value\\:\\ \ \(0\)\
\-\ \\Â\\»\\:\\ 0\\.10431042931928484\ \(0\)\
\-\ drop\\:\\ 0\\.07108338327671736\ \(0\)\
\-\ metastases\\:\\ 0\\.06577896306383756\ \(0\)\
\-\ roots\\:\\ 0\\.057182982045981184\ \(0\)\
\-\ arachnoiditis\\:\\ 0\\.04868973318602972\ \(0\)\
\-\ spread\\:\\ 0\\.04654715311759322\ \(0\)\
\-\ hematogenous\\:\\ 0\\.03729514566190655\ \(0\)\
\-\ nerve\\:\\ 0\\.03467281673972192\ \(0\)\
\-\ medulloblastoma\\:\\ 0\\.03354980285308406\ \(0\)\
\-\ csf\\:\\ 0\\.03214859776401813\ \(0\)\
\-\ choroid\\:\\ 0\\.02946737248454723\ \(0\)\
\-\ tumors\\:\\ 0\\.028916363582617125\ \(0\)\
\-\ seeding\\:\\ 0\\.028908212392649225\ \(0\)\
\-\ breast\\:\\ 0\\.028401422917392363\ \(0\)\
\-\ plexus\\:\\ 0\\.028054590066583996\ \(0\)\
\-\ spinal\\:\\ 0\\.027565551444861135\ \(0\)\
\-\ ependymoma\\:\\ 0\\.02584517457559299\ \(0\)\
\-\ cauda\\:\\ 0\\.025785927795532352\ \(0\)\
\-\ equina\\:\\ 0\\.025785927795532352\ \(0\)\
\-\ lesions\\:\\ 0\\.02576081651288229\ \(0\)\
\-\ surface\\:\\ 0\\.025487116939508458\ \(0\)\
\-\ may\\:\\ 0\\.02532876174186654\ \(0\)\
\-\ nodular\\:\\ 0\\.02421898518318859\ \(0\)\
\-\ neurofibromatosis\\:\\ 0\\.02126654892677657\ \(0\)\
\-\ \\-\\:\\ 0\\.02062757273320229\ \(0\)\
\-\ likley\\:\\ 0\\.01985477122514977\ \(0\)\
\-\ lower\\-thoracic\\:\\ 0\\.01985477122514977\ \(0\)\
\-\ melanoma\\:\\ 0\\.019644914989698153\ \(0\)\
\-\ cancer\\:\\ 0\\.01898084638084301\ \(0\)\
\-\ granulomatous\\:\\ 0\\.0185773447826007\ \(0\)\
\-\ droplet\\:\\ 0\\.018293628926591334\ \(0\)\
\-\ clumping\\:\\ 0\\.018293628926591334\ \(0\)\
\-\ prognosis\\:\\ 0\\.01825830850976911\ \(0\)\
\-\ such\\:\\ 0\\.018049545877303057\ \(0\)\
\-\ or\\:\\ 0\\.01804545493628302\ \(0\)\
\-\ breach\\:\\ 0\\.01738041922364502\ \(0\)\
\-\ hematogenously\\:\\ 0\\.0167324866280329\ \(0\)\
\-\ 43\\-year\\-old\\:\\ 0\\.016229911062009904\ \(0\)\
\-\ witheld\\:\\ 0\\.015819276925086584\ \(0\)\
\-\ enhancement\\:\\ 0\\.01547627544677727\ \(0\)\
\-\ nf2\\:\\ 0\\.015472090709259425\ \(0\)\
\-\ posture\\:\\ 0\\.015171344329474465\ \(0\)\
\-\ pial\\:\\ 0\\.014906067222140267\ \(0\)\
\-\ pineoblastoma\\:\\ 0\\.01466876876345147\ \(0\)\
\-\ dissemination\\:\\ 0\\.01466876876345147\ \(0\)\
\-\ cord\\:\\ 0\\.01462690955047478\ \(0\)\
\-\ occur\\:\\ 0\\.014441651480997922\ \(0\)\
\-\ neurofibromas\\:\\ 0\\.014258134626528148\ \(0\)\
\-\ piece\\:\\ 0\\.01391094841070099\ \(0\)\
\-\ gravity\\:\\ 0\\.01391094841070099\ \(0\)\
\-\ they\\:\\ 0\\.013869126695888766\ \(0\)\
\-\ neuroectodermal\\:\\ 0\\.013610202030916028\ \(0\)\
\-\ germinoma\\:\\ 0\\.013610202030916028\ \(0\)\
\-\ typically\\:\\ 0\\.013587503466243118\ \(0\)\
\-\ nf1\\:\\ 0\\.013473660089888023\ \(0\)\
\-\ are\\:\\ 0\\.013117949014972992\ \(0\)\
\-\ extramedullary\\:\\ 0\\.012997738707754673\ \(0\)\
\-\ implants\\:\\ 0\\.012997738707754673\ \(0\)\
\-\ areas\\:\\ 0\\.012952014284892193\ \(0\)\
\-\ non\\-hodgkin\\:\\ 0\\.012792847315399434\ \(0\)\
\-\ along\\:\\ 0\\.012720963409272595\ \(0\)\
\-\ spine\\:\\ 0\\.012676142099123188\ \(0\)\
\-\ primitive\\:\\ 0\\.01251671595933562\ \(0\)\
\-\ responsible\\:\\ 0\\.01251671595933562\ \(0\)\
\-\ deposits\\:\\ 0\\.012431715220635516\ \(0\)\
\-\ intradural\\:\\ 0\\.012431715220635516\ \(0\)\
\-\ consist\\:\\ 0\\.012431715220635516\ \(0\)\
\-\ carcinomas\\:\\ 0\\.012349806112142554\ \(0\)\
\-\ \\.\\.\\.\\:\\ 0\\.012194416761946717\ \(0\)\
\-\ access\\:\\ 0\\.012194416761946717\ \(0\)\
\-\ anaplastic\\:\\ 0\\.012120565809642684\ \(0\)\
\-\ upright\\:\\ 0\\.012120565809642684\ \(0\)\
\-\ pineal\\:\\ 0\\.012049059732357594\ \(0\)\
\-\ post\\-gadolinium\\:\\ 0\\.011979754194819859\ \(0\)\
\-\ usually\\:\\ 0\\.011688866008408825\ \(0\)\
\-\ pnet\\:\\ 0\\.011662009604144397\ \(0\)\
\-\ detect\\:\\ 0\\.011662009604144397\ \(0\)\
\-\ diffuse\\:\\ 0\\.011653186578267184\ \(0\)\
\-\ as\\:\\ 0\\.011644842395442593\ \(0\)\
\-\ brain\\:\\ 0\\.011582664519381811\ \(0\)\
\-\ craniotomy\\:\\ 0\\.011546484166334598\ \(0\)\
\-\ oligodendroglioma\\:\\ 0\\.011281207059000403\ \(0\)\
\-\ multiforme\\:\\ 0\\.011183267617694684\ \(0\)\
\-\ lung\\:\\ 0\\.011149365406480838\ \(0\)\
\-\ mets\\:\\ 0\\.01108941019336908\ \(0\)\
\-\ carcinoma\\:\\ 0\\.01090958409917057\ \(0\)\
\-\ resulted\\:\\ 0\\.01087057292207708\ \(0\)\
\-\ contents\\:\\ 0\\.01087057292207708\ \(0\)\
\-\ has\\:\\ 0\\.01084256736820458\ \(0\)\
\-\ glioblastoma\\:\\ 0\\.01059604630584051\ \(0\)\
\-\ modality\\:\\ 0\\.01055942351108425\ \(0\)\
\-\ sites\\:\\ 0\\.010487917433799157\ \(0\)\
\-\ processes\\:\\ 0\\.010418611896261424\ \(0\)\
\-\ \\,\\:\\ 0\\.010365025031067308\ \(0\)\
\-\ probably\\:\\ 0\\.010254140871453115\ \(0\)\
\-\ common\\:\\ 0\\.01007327572953332\ \(0\)\
\-\ population\\:\\ 0\\.01004236395783087\ \(0\)\
\-\ these\\:\\ 0\\.010017318432242522\ \(0\)\
\-\ depending\\:\\ 0\\.010013672458332155\ \(0\)\
\-\ germ\\:\\ 0\\.009957363219130764\ \(0\)\
\-\ helpful\\:\\ 0\\.009957363219130764\ \(0\)\
\-\ cns\\:\\ 0\\.009848799926748157\ \(0\)\
\-\ neoplasms\\:\\ 0\\.009796419606558367\ \(0\)\
\-\ dorsal\\:\\ 0\\.009796419606558367\ \(0\)\
\-\ metastatic\\:\\ 0\\.009689681998270677\ \(0\)\
\-\ to\\:\\ 0\\.009618651091058248\ \(0\)\
\-\ number\\:\\ 0\\.009598291739562967\ \(0\)\
\-\ extent\\:\\ 0\\.009551368120412422\ \(0\)\
\-\ aggressive\\:\\ 0\\.00941619242283077\ \(0\)\
\-\ subarachnoid\\:\\ 0\\.009351530022194665\ \(0\)\
\-\ pediatric\\:\\ 0\\.009268103734626311\ \(0\)\
\-\ improved\\:\\ 0\\.009167987152259569\ \(0\)\
\-\ epidermoid\\:\\ 0\\.009167987152259569\ \(0\)\
\-\ hypointense\\:\\ 0\\.009129154254884555\ \(0\)\
\-\ direct\\:\\ 0\\.009090979573997677\ \(0\)\
\-\ steroids\\:\\ 0\\.009053441167499452\ \(0\)\
\-\ tumor\\:\\ 0\\.008974019376625276\ \(0\)\
\-\ received\\:\\ 0\\.008944439949342133\ \(0\)\
\-\ like\\:\\ 0\\.00890924779190276\ \(0\)\
\-\ woman\\:\\ 0\\.008891454718418497\ \(0\)\
\-\ demonstrate\\:\\ 0\\.00885789252852721\ \(0\)\
\-\ local\\:\\ 0\\.008840471386812487\ \(0\)\
\-\ schwannoma\\:\\ 0\\.008790233194212717\ \(0\)\
\-\ removed\\:\\ 0\\.008677193229068899\ \(0\)\
\-\ generally\\:\\ 0\\.008661498027906526\ \(0\)\
\-\ poor\\:\\ 0\\.008661498027906526\ \(0\)\
\-\ ventricular\\:\\ 0\\.008599788626581943\ \(0\)\
\-\ from\\:\\ 0\\.008556998061852786\ \(0\)\
\-\ via\\:\\ 0\\.008261315196290642\ \(0\)\
\-\ lumbar\\:\\ 0\\.00818408755332075\ \(0\)\
\-\ linear\\:\\ 0\\.00815892246188353\ \(0\)\
\-\ best\\:\\ 0\\.00809721306055895\ \(0\)\
\-\ position\\:\\ 0\\.008013565432294407\ \(0\)\
\-\ hyperintense\\:\\ 0\\.007990225821853986\ \(0\)\
\-\ history\\:\\ 0\\.007974422552074888\ \(0\)\
\-\ related\\:\\ 0\\.007944259894756674\ \(0\)\
\-\ occurs\\:\\ 0\\.00789921334812003\ \(0\)\
\-\ where\\:\\ 0\\.007855050124272336\ \(0\)\
\-\ evaluate\\:\\ 0\\.007779788869948363\ \(0\)\
\-\ narrowing\\:\\ 0\\.007717222284121615\ \(0\)\
\-\ canal\\:\\ 0\\.007646359064626604\ \(0\)\
\-\ use\\:\\ 0\\.007606844853701132\ \(0\)\
\-\ also\\:\\ 0\\.0075883765480637445\ \(0\)\
\-\ system\\:\\ 0\\.0075776575909927875\ \(0\)\
\-\ similar\\:\\ 0\\.007548843736353352\ \(0\)\
\-\ previous\\:\\ 0\\.00747376170872364\ \(0\)\
\-\ astrocytoma\\:\\ 0\\.00747376170872364\ \(0\)\
\-\ about\\:\\ 0\\.007419048437171738\ \(0\)\
\-\ management\\:\\ 0\\.007262458205981174\ \(0\)\
\-\ \\â\\€\\¢\\:\\ 0\\.007058623205386882\ \(0\)\
\-\ cortical\\:\\ 0\\.00701593434814372\ \(0\)\
\-\ presence\\:\\ 0\\.006986003645173714\ \(0\)\
\-\ peripheral\\:\\ 0\\.006963813788320084\ \(0\)\
\-\ malignant\\:\\ 0\\.006956465487340768\ \(0\)\
\-\ chemotherapy\\:\\ 0\\.006898526543110056\ \(0\)\
\-\ status\\:\\ 0\\.006870106579237958\ \(0\)\
\-\ the\\:\\ 0\\.006850189782612089\ \(0\)\
\-\ new\\:\\ 0\\.006706729677478735\ \(0\)\
\-\ cerebral\\:\\ 0\\.00666767230127043\ \(0\)\
\-\ that\\:\\ 0\\.00664856184035506\ \(0\)\
\-\ less\\:\\ 0\\.006517882892618654\ \(0\)\
\-\ cause\\:\\ 0\\.006511852762504428\ \(0\)\
\-\ is\\:\\ 0\\.006332103360188352\ \(0\)\
\-\ radiation\\:\\ 0\\.006315881192707965\ \(0\)\
\-\ disease\\:\\ 0\\.006291610546016685\ \(0\)\
\-\ mr\\:\\ 0\\.006115314126005482\ \(0\)\
\-\ differential\\:\\ 0\\.006110269885930022\ \(0\)\
\-\ t1\\:\\ 0\\.006100215171676224\ \(0\)\
\-\ and\\:\\ 0\\.006081385328791164\ \(0\)\
\-\ found\\:\\ 0\\.006065373005522776\ \(0\)\
\-\ post\\:\\ 0\\.006060439263676337\ \(0\)\
\-\ be\\:\\ 0\\.0059358410961438245\ \(0\)\
\-\ clinical\\:\\ 0\\.005921868919067577\ \(0\)\
\-\ show\\:\\ 0\\.005908008861467626\ \(0\)\
\-\ treated\\:\\ 0\\.005760925306495178\ \(0\)\
\-\ primary\\:\\ 0\\.00570131590742274\ \(0\)\
\-\ lymphoma\\:\\ 0\\.005500447374751094\ \(0\)\
\-\ t2\\:\\ 0\\.005447272001689982\ \(0\)\
\-\ likely\\:\\ 0\\.0054285810043595865\ \(0\)\
\-\ she\\:\\ 0\\.005402671489761649\ \(0\)\
\-\ if\\:\\ 0\\.005222395121127557\ \(0\)\
\-\ cell\\:\\ 0\\.005198740341399744\ \(0\)\
\-\ therapy\\:\\ 0\\.0051455873789203\ \(0\)\
\-\ due\\:\\ 0\\.005135759353497387\ \(0\)\
\-\ on\\:\\ 0\\.004891155488955595\ \(0\)\
\-\ \\`\\`\\:\\ 0\\.0047300338685401285\ \(0\)\
\-\ surgery\\:\\ 0\\.004673421316126745\ \(0\)\
\-\ \\'\\'\\:\\ 0\\.004639075454914962\ \(0\)\
\-\ imaging\\:\\ 0\\.0045091752803054115\ \(0\)\
\-\ most\\:\\ 0\\.00444332239127945\ \(0\)\
\-\ this\\:\\ 0\\.004329446906820419\ \(0\)\
\-\ have\\:\\ 0\\.004167653329651108\ \(0\)\
\-\ of\\:\\ 0\\.0039359392161482576\ \(0\)\
\-\ in\\:\\ 0\\.003796371442704999\ \(0\)\
\-\ images\\:\\ 0\\.0036920357926787254\ \(0\)\
\-\ a\\:\\ 0\\.0035729711875549662\ \(0\)\
\-\ for\\:\\ 0\\.00328427093983205\ \(0\)\
\-\ \\(\\:\\ 0\\.0032538816497471195\ \(0\)\
\-\ \\)\\:\\ 0\\.003214133748258131\ \(0\)\
\-\ \\:\\:\\ 0\\.002545663999978975\ \(0\)\
\-\ was\\:\\ 0\\.002225850275256051\ \(0\)\
\-\ \\.\\:\\ 0\\.0015191242924540074\ \(0\)\
\-\ with\\:\\ 0\\.0007905687573641198\ \(0\)\
